Literature DB >> 16611193

Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens.

W L Irving1, S Smith, R Cater, S Pugh, K R Neal, C A C Coupland, S D Ryder, B J Thomson, M Pringle, M Bicknell, J Hippisley-Cox.   

Abstract

Management of hepatitis C virus (HCV)-infected individuals requires referral to specialist care. To determine whether patients newly diagnosed as anti-HCV positive are appropriately referred for further investigation and management, and if not, to determine why not. We studied patients tested for antibodies to HCV by Nottingham Public Health Laboratory in a 2-year period (2000-2002). The progress of newly diagnosed anti-HCV positive patients into specialist clinics for further management was documented. For patients not referred for specialist care, a questionnaire was sent to the clinician requesting the initial anti-HCV test, to identify reasons for nonreferral. Eleven thousand one hundred and seventy-seven patients were tested for anti-HCV. Two hundred and fifty-six (2.3%) were newly diagnosed as being anti-HCV positive. Two per cent of samples sent from primary care were anti-HCV positive, compared to 18.8, 18.9 and 1.3% sent from prison, drug and alcohol units, and secondary care, respectively. About 64.3% of positive patients diagnosed in primary care were referred to specialist care, compared to 18.4, 42.4 and 62.6% of patients diagnosed in the other three settings. One hundred and twenty-five (49%) newly diagnosed patients were referred appropriately for further management. 68 of these attended clinic, 45 underwent liver biopsy and 26 (10%) began treatment. One hundred and thirty-one patients (51%) were not referred. In 54 cases, there was no evidence that the anti-HCV positive result reached the patient. In 15, referral was considered but rejected, and 20 patients were referred to non-HCV-specialists (their general practitioners or to genito-urinary medicine). Hence less than 50% of newly diagnosed anti-HCV positive patients are referred to an appropriate clinic for further investigation and management. Reasons for this are multifarious and complex, reflecting both systems failure and patient choice. Unless these are understood and addressed, the Department of Health Hepatitis C Strategy (2002) and Action Plan for England (2004) will fail to achieve their intended objectives.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611193     DOI: 10.1111/j.1365-2893.2005.00698.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  24 in total

1.  Chronic hepatitis C.

Authors:  Kosh Agarwal; Timothy J S Cross; Charles Gore
Journal:  BMJ       Date:  2007-01-13

Review 2.  Demographics of hepatitis C virus today.

Authors:  Stevan A Gonzalez; Gary L Davis
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-03-06

Review 3.  Novel interventions to prevent HIV and HCV among persons who inject drugs.

Authors:  Phillip O Coffin; Christopher Rowe; Glenn-Milo Santos
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

4.  Developing a community HCV service: project ITTREAT (integrated community-based test - stage - TREAT) service for people who inject drugs.

Authors:  Ahmed Hashim; Margaret O'Sullivan; Hugh Williams; Sumita Verma
Journal:  Prim Health Care Res Dev       Date:  2017-12-04       Impact factor: 1.458

5.  Improving access to treatment for patients with chronic hepatitis C through outreach.

Authors:  Ahmed Mohamed Elsharkawy; Carolyn Miller; Andrea Hearn; Gertrud Buerstedde; Ashley Price; Stuart McPherson
Journal:  Frontline Gastroenterol       Date:  2012-12-14

Review 6.  Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.

Authors:  Jaimie P Meyer; Yavar Moghimi; Ruthanne Marcus; Joseph K Lim; Alain H Litwin; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2015-05-17

7.  Cost-effectiveness and population outcomes of general population screening for hepatitis C.

Authors:  Phillip O Coffin; John D Scott; Matthew R Golden; Sean D Sullivan
Journal:  Clin Infect Dis       Date:  2012-03-12       Impact factor: 9.079

8.  Capacity enhancement of hepatitis C virus treatment through integrated, community-based care.

Authors:  Warren D Hill; Gail Butt; Maria Alvarez; Mel Krajden
Journal:  Can J Gastroenterol       Date:  2008-01       Impact factor: 3.522

Review 9.  Best strategies for global HCV eradication.

Authors:  Liesl M Hagan; Raymond F Schinazi
Journal:  Liver Int       Date:  2013-02       Impact factor: 5.828

Review 10.  HepCare Ireland-a service innovation project.

Authors:  Stephen P Connolly; Gordana Avramovic; Walter Cullen; Tina McHugh; Eileen O'Connor; Geoff Mc Combe; Des Crowley; Anna Marie Naughton; Aidan Horan; John S Lambert
Journal:  Ir J Med Sci       Date:  2020-08-06       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.